PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.

Trial Details

NCT ID
NCT07190469
Phase
PHASE1
Sponsor
ProteinQure Inc.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • PQ203
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327
  • San Antonio, Texas, United States|29.42412,-98.49363
  • West Valley City, Utah, United States|40.69161,-112.00105
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • At least 18 years old
  • Histologically or cytologically documented metastatic or locally advanced solid tumor malignancies having progressed through or being otherwise ine…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Documented presence of RECIST v1.1 measurable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →